Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017 (2017), Article ID 6894374, 19 pages
https://doi.org/10.1155/2017/6894374
Clinical Study

T-Cell Subsets in Rheumatoid Arthritis Patients on Long-Term Anti-TNF or IL-6 Receptor Blocker Therapy

1Department of Rheumatology and Immunology, Faculty of Medicine, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary
2First Department of Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary
3First Department of Pediatrics, Semmelweis University, Budapest, Hungary
4Department of Laboratory Medicine, Semmelweis University, Budapest, Hungary

Correspondence should be addressed to Gergely Toldi; moc.oohay@ylegregidlot

Received 14 February 2017; Revised 22 May 2017; Accepted 19 July 2017; Published 25 October 2017

Academic Editor: Tânia Silvia Fröde

Copyright © 2017 Sonja Dulic et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. B. McInnes, C. D. Buckley, and J. D. Isaacs, “Cytokines in rheumatoid arthritis -- shaping the immunological landscape,” Nature Reviews Rheumatology, vol. 12, no. 1, pp. 63–68, 2016. View at Publisher · View at Google Scholar
  2. D. Aeberli, M. Seitz, P. Jüni, and P. M. Villiger, “Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-α inhibitors,” Rheumatology, vol. 44, no. 2, pp. 172–175, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. P. T. Yang, H. Kasai, L. J. Zhao, W. G. Xiao, F. Tanabe, and M. Ito, “Increased CCR4 expression on circulating CD4+ T cells in ankylosing spondylitis, rheumatoid arthritis, and systemic lupus erythematosus,” Clinical and Experimental Immunology, vol. 138, no. 2, pp. 342–347, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. K. M. Chavele and M. R. Ehrenstein, “Regulatory T cells in systemic lupus erythematosus and rheumatoid arthritis,” FEBS Letters, vol. 585, no. 23, pp. 3603–3610, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. S. L. Gaffen, “The role of interleukin-17 in the pathogenesis of rheumatoid arthritis,” Current Rheumatology Reports, vol. 11, pp. 365–370, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Byng-Maddick and M. R. Ehrenstein, “The impact of biological therapy on regulatory T cells in rheumatoid arthritis,” Rheumatology, vol. 54, no. 5, pp. 768–775, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Szalay, B. Vásárhelyi, A. Cseh et al., “The impact of conventional DMARD and biological therapies on CD4+ cell subsets in rheumatoid arthritis: a follow-up study,” Clinical Rheumatology, vol. 33, no. 2, pp. 175–185, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Yue, X. You, L. Zhao et al., “The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients,” Rheumatology International, vol. 30, pp. 1553–1557, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. O. Aravena, B. Pescea, L. Soto et al., “Anti-TNF therapy in patients with rheumatoid arthritis decreases Th1 and Th17 cell populations and expands IFN-γ-producing NK cell and regulatory T cell subsets,” Immunobiology, vol. 216, pp. 1256–1263, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. D. N. Hull, R. O. Williams, E. Pathan, S. Alzabin, S. Abraham, and P. C. Taylor, “Anti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis,” Clinical and Experimental Immunology, vol. 181, no. 3, pp. 401–406, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. Z. Huang, B. Yang, Y. Shi et al., “Anti-TNF-α therapy improves Treg and suppresses Teff in patients with rheumatoid arthritis,” Cellular Immunology, vol. 279, no. 1, pp. 25–29, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Lina, W. Conghua, L. Nan, and Z. Ping, “Combined treatment of etanercept and MTX reverses Th1/Th2, Th17/Treg imbalance in patients with rheumatoid arthritis,” Journal of Clinical Immunology, vol. 31, pp. 596–605, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Herman, N. Zurgil, S. Machlav et al., “Distinct effects of anti-tumor necrosis factor combined therapy on TH1/TH2 balance in rheumatoid arthritis patients,” Clinical and Vaccine Immunology, vol. 18, no. 7, pp. 1077–1082, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Y. Chen, Y. M. Chen, H. H. Chen, C. W. Hsieh, C. C. Lin, and J. L. Lan, “Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy,” Arthritis Research & Therapy, vol. 13, pp. R126–R135, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Blache, T. Lequerré, A. Roucheux et al., “Number and phenotype of rheumatoid arthritis patients’ CD4+CD25hi regulatory T cells are not affected by adalimumab or etanercept,” Rheumatology, vol. 50, no. 10, pp. 1814–1822, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Kikuchi, M. Hashizume, Y. Kaneko, K. Yoshimoto, N. Nishina, and T. Takeuchi, “Peripheral blood CD4+ CD25+ CD127low regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response,” Arthritis Research & Therapy, vol. 17, pp. 10–19, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. B. Pesce, L. Soto, F. Sabugo et al., “Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients,” Clinical and Experimental Immunology, vol. 171, no. 3, pp. 237–242, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Samson, S. Audia, N. Janikashvili et al., “Inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis,” Arthritis and Rheumatism, vol. 64, no. 8, pp. 2499–2503, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. S. R. Greisen, H. J. Møller, K. Stengaard-Pedersen et al., “Macrophage activity assessed by soluble CD163 in early rheumatoid arthritis: association with disease activity but different response patterns to synthetic and biologic DMARDs,” Clinical and Experimental Rheumatology, vol. 33, no. 4, pp. 498–502, 2015. View at Google Scholar
  20. M. de La Forest Divonne, J. E. Gottenberg, and C. Salliot, “Safety of biologic DMARDs in RA patients in real life: a systematic literature review and meta-analyses of biologic registers,” Joint, Bone, Spine, vol. 84, no. 2, pp. 133–140, 2017. View at Publisher · View at Google Scholar · View at Scopus
  21. A. A. Chokoeva, G. Tchernev, T. Lotti, and U. Wollina, “Extrinsic apoptotic pathways, anti-TNF-alpha therapy and cancer progression: more and more clinical data support this critical relationship?” Dermatologic Therapy, vol. 28, no. 4, pp. 216-217, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Sode, U. Vogel, S. Bank et al., “Confirmation of an IRAK3 polymorphism as a genetic marker predicting response to anti-TNF treatment in rheumatoid arthritis,” The Pharmacogenomics Journal, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Aletaha, T. Neogi, A. J. Silman et al., “2010 rheumatoid arthritis classification criteria. An American college of rheumatology/European league against rheumatism collaborative initiative,” Arthritis and Rheumatism, vol. 62, no. 9, pp. 2569–2581, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. A. M. van Gestel, C. J. Haagsma, and P. L. van Riel, “Validation of rheumatoid arthritis improvement criteria that include simplified joint counts,” Arthritis and Rheumatism, vol. 41, no. 10, pp. 1845–1850, 1998. View at Publisher · View at Google Scholar
  25. A. Teniente-Serra, L. Grau-López, M. J. Mansilla et al., “Multiparametric flow cytometric analysis of whole blood reveals changes in minor lymphocyte subpopulations of multiple sclerosis patients,” Autoimmunity, vol. 49, no. 4, pp. 219–228, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. E. Besada and J. C. Nossent, “CD4 cell count and CD4/CD8 ratio increase during rituximab maintenance in granulomatosis with polyangiitis patients,” PeerJ, vol. 4, article e2487, 2016. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Sottini, R. Capra, C. Zanotti et al., “Pre-existing T- and B-cell defects in one progressive multifocal leukoencephalopathy patient,” PLoS One, vol. 7, no. 4, article e34493, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Sancho, M. Gómez, and F. Sánchez-Madrid, “CD69 is an immunoregulatory molecule induced following activation,” Trends in Immunology, vol. 26, no. 3, pp. 136–140, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. E. M. Shevach, “CD4+ CD25+ supressor T cells: more questions than answers,” Nature Reviews Immunology, vol. 2, no. 6, pp. 389–402, 2002. View at Publisher · View at Google Scholar
  30. T. M. Holling, N. van der Stoep, E. Quinten, and P. J. van den Elsen, “Activated human T cells accomplish MHC class II expression through T cell-specific occupation of class II transactivator promoter III,” Journal of Immunology, vol. 168, no. 2, pp. 763–770, 2002. View at Publisher · View at Google Scholar
  31. K. Shiozawa, T. Yamane, M. Murata et al., “MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy,” Arthritis Research & Therapy, vol. 18, p. 55, 2016. View at Publisher · View at Google Scholar · View at Scopus
  32. N. Carrier, A. Marotta, A. J. de Brum-Fernandes et al., “Serum levels of 14-3-3η protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis,” Arthritis Research & Therapy, vol. 18, p. 37, 2016. View at Publisher · View at Google Scholar · View at Scopus
  33. R. Seror, S. Boudaoud, S. Pavy et al., “Increased Dickkopf-1 in recent-onset rheumatoid arthritis is a new biomarker of structural severity. Data from the ESPOIR Cohort,” Scientific Reports, vol. 6, article 18421, 2016. View at Publisher · View at Google Scholar · View at Scopus
  34. J. S. Smolen, D. Aletaha, J. W. Bijlsma et al., “Treating rheumatoid arthritis to target: recommendations of an international task force,” Annals of the Rheumatic Diseases, vol. 69, no. 4, pp. 631–637, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. R. F. van Vollenhoven, M. Mosca, G. Bertsias et al., “Treat-to-target in systemic lupus erythematosus: recommendations from an international task force,” Annals of the Rheumatic Diseases, vol. 73, no. 6, pp. 958–967, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. J. S. Smolen, J. Braun, M. Dougados et al., “Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force,” Annals of the Rheumatic Diseases, vol. 73, no. 1, pp. 6–16, 2014. View at Publisher · View at Google Scholar · View at Scopus